Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PDL1 Gene Mutation”

41 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 41 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05445843
What this trial is testing

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Who this might be right for
Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
Novartis Pharmaceuticals 95
Testing effectiveness (Phase 2)WithdrawnNCT04754815
What this trial is testing

Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC

Who this might be right for
Non Small Cell Lung CancerAdvanced Lung Non-Small Cell CarcinomaPD-L1 Gene Mutation
Shirish Gadgeel
Testing effectiveness (Phase 2)UnknownNCT04023916
What this trial is testing

Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.

Who this might be right for
Diffuse Large B-Cell LymphomaSintilimabTP53 Mutation
Chinese Academy of Medical Sciences 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT04716946
What this trial is testing

Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy

Who this might be right for
NSCLCNon-small Cell Lung CancerLung Cancer+5 more
Memorial Sloan Kettering Cancer Center 13
Testing effectiveness (Phase 2)Ended earlyNCT04925986
What this trial is testing

Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell LungLung DiseasesLung Neoplasms+6 more
Sarah Goldberg 9
Not applicableActive Not RecruitingNCT06876402
What this trial is testing

Gene Molecular Alterations as Disease Prognostic Markers in Patients With Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)
Hellenic Cooperative Oncology Group 367
Not applicableLooking for participantsNCT06430502
What this trial is testing

Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory Advanced Solid Tumours

Who this might be right for
CancerPD-L1 Gene Mutation
Wuxi People's Hospital 200
Early research (Phase 1)Study completedNCT02027961
What this trial is testing

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Who this might be right for
Melanoma
MedImmune LLC 68
Not applicableUnknownNCT05527808
What this trial is testing

A Single-arm Exploratory Study of Neoadjuvant Therapy

Who this might be right for
Lung Adenocarcinoma
Jun Liu 28
Testing effectiveness (Phase 2)Looking for participantsNCT06501391
What this trial is testing

Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis

Who this might be right for
NSCLC Stage IVBrain Metastases
Fudan University 54
Not applicableUnknownNCT04405661
What this trial is testing

Correlation Between Specific Gene Mutationand Local Immune Microenvironment and Immunotherapy Efficacy in NSCLC

Who this might be right for
NSCLC
Guangzhou Institute of Respiratory Disease 100
Testing effectiveness (Phase 2)Study completedNCT04426825
What this trial is testing

Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Hoffmann-La Roche 23
Testing effectiveness (Phase 2)UnknownNCT04940637
What this trial is testing

UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC

Who this might be right for
Lung CancerMesothelioma
University of Turin, Italy 70
Testing effectiveness (Phase 2)Looking for participantsNCT06501378
What this trial is testing

Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Active Brain Metastasis

Who this might be right for
NSCLC Stage IV
Fudan University 40
Not applicableUnknownNCT04191226
What this trial is testing

Genetic Mutation in Recurrent Cervical Cancer

Who this might be right for
Recurrent Cervical CancerNucleotide VariantCopy Number Variation+6 more
Lei Li 300
Testing effectiveness (Phase 2)UnknownNCT05266937
What this trial is testing

Atezolizumab Plus CArboplatin Plus Nab-paclitaxel

Who this might be right for
Metastatic Breast CancerTriple Negative Breast CancerPD-L1 Gene Mutation
Consorzio Oncotech 49
Early research (Phase 1)Study completedNCT01656642
What this trial is testing

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Genentech, Inc. 67
Not applicableLooking for participantsNCT07279402
What this trial is testing

TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%

Who this might be right for
NSCLC Stage IVPD-L1 Gene MutationAtezolizumab+1 more
Antalya Training and Research Hospital 150
Early research (Phase 1)Looking for participantsNCT05787587
What this trial is testing

PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced or Metastatic Solid TumorsBreast CancerOvarian Cancer+6 more
IDEAYA Biosciences 216
Testing effectiveness (Phase 2)UnknownNCT05394233
What this trial is testing

Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC

Who this might be right for
Non-squamous Non-small Cell Lung CancerEGFR Gene Mutation
Sichuan Cancer Hospital and Research Institute 20
Load More Results